血清Lipocalin-2和YKL-40联合检测对食管癌患者新辅助放化疗效果的预测价值

doi:10.3969/j.issn.1004-616x.2025.04.014

Abstract

Abstract: OBJECTIVE： To investigate the levels of Lipocalin-2 and YKL-40 in serum samples from esophageal cancer (EC) patients and their relationship with therapeutic effect of neoadjuvant radiotherapy and chemotherapy. METHODS： From January 2021 to August 2022，a total of 200 EC patients who underwent neoadjuvant radiotherapy and chemotherapy in the Hankuang General Hospital of North China Medical and Health Group were recruited as research subjects. All patients were examined 5 cycles after treatment，according to the therapeutic effect of patients. They were grouped into effective (128 cases) and ineffective groups (72 cases). The contents of serum Lipocalin-2，YKL-40 and carcinoembryonic antigen (CEA) were compared between the two groups before treatment；logistic regression was applied to analyze the influencing factors of neoadjuvant radiotherapy and chemotherapy therapeutic effect in EC patients. Receiver operating characteristic (ROC) was applied to analyze the predictive value of serum Lipocalin-2，YKL-40 and CEA in the therapeutic effect among the patients. RESULTS： Compared with the effective group，the contents of serum Lipocalin-2，YKL-40，and CEA in the ineffective group were significantly increased (P<0.05). Serum Lipocalin-2，YKL-40，and CEA were the factors for the therapeutic effect of the two therapies (P<0.05). ROC curve showed that the AUC of combined serum Lipocalin-2，YKL-40 and CEA predicted the efficacy of the therapy at 0.975，with sensitivity of 95.65%，and specificity of 89.29%. It was better than the three individual predictions (Z_{combination-Lipocalin-2}=23.868，P<0.01；Z_{combination-YKL-40}=3.918，P<0.01；Z_{combination-CEA}=3.742，P<0.01). CONCLUSION： Serum Lipocalin-2 and YKL-40 contents were significantly increased in patients who did not respond to EC neoadjuvant chemoradiotherapy，and the combination of Lipocalin-2 and YKL-40 with the traditional tumor marker CEA has good reference value in predicting the therapeutic effect of neoadjuvant radiotherapy and chemotherapy for EC.

Key words: lipocalin, chitosanase 3-like protein 1, esophageal cancer, neoadjuvant radiotherapy and chemotherapy, therapeutic effect

CLC Number:

R735.1

YANG Zhihui, HAN Xianglong, LIU Gengang, SHI Jie. Relationships between serum Lipocalin-2 and YKL-40 levels on therapeutic effect of neoadjuvant radiotherapy and chemotherapy in esophageal cancer patients[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 310-313,318.

References

[1] LI D P, ZHANG L, LIU Y P, et al. Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer[J]. Aging, 2019, 11(23): 11640-11658.
[2] WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surg Today, 2020, 50(1): 12-20.
[3] GE F, HUO Z Y, CAI X Y, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis[J]. JAMA Netw Open, 2022, 5(11): e2239778.
[4] SIHAG S, KU G Y, TAN K S, et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer[J]. J Thorac Cardiovasc Surg, 2021, 161(3): 836-843.e1.
[5] 鲁为山, 陈晟, 方军. 复方苦参注射液联合放化疗对老年食管癌患者血清CEA、CA199和CA125水平及细胞免疫功能的影响[J]. 中国老年学杂志, 2020, 40(6): 1186-1189.
[6] JABERI S A, COHEN A, D’SOUZA C, et al. Lipocalin-2: Structure, function, distribution and role in metabolic disorders[J]. Biomed Pharmacother, 2021, 142: 112002.
[7] CHAUDHARY N, CHOUDHARY B S, SHAH S G, et al. Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer[J]. Int J Cancer, 2021, 149(7): 1495-1511.
[8] ZHAO T, SU Z P, LI Y C, et al. Chitinase-3 like-protein-1 function and its role in diseases[J]. Signal Transduct Target Ther, 2020, 5(1): 201.
[9] TIZAOUI K, YANG J W, LEE K H, et al. The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review[J]. Int J Biol Sci, 2022, 18(9): 3731-3746.
[10] 中国抗癌协会胃癌专业委员会. 胃癌诊治难点中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(8): 869-904.
[11] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[12] LIU K C, ZHAO T T, WANG J K, et al. Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer[J]. Cancer Lett, 2019, 458: 21-28.
[13] HAN J M, WANG Z T, LIU C X. Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis[J]. Future Oncol, 2021, 17(17): 2257-2274.
[14] SANTIAGO-SÁNCHEZ G S, PITA-GRISANTI V, QUI-ONES-DíAZ B, et al. Biological functions and therapeutic potential of lipocalin 2 in cancer[J]. Int J Mol Sci, 2020, 21(12): 4365.
[15] HU C X, YANG K, LI M J, et al. Lipocalin 2: a potential therapeutic target for breast cancer metastasis[J]. Onco Targets Ther, 2018, 11: 8099-8106.
[16] DENG M, ABERLE M R, VAN BIJNEN A A J H M, et al. Lipocalin-2 and neutrophil activation in pancreatic cancer Cachexia[J]. Front Immunol, 2023, 14: 1159411.
[17] WANG F, ZHANG C Q, CHENG H, et al. TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2[J]. Cell Death Dis, 2021, 12(10): 901.
[18] HAO H L, CHEN H Q, XIE L W, et al. YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition[J]. Ann Med, 2021, 53(1): 1170-1178.
[19] DE ROBERTIS M, GRECO M R, CARDONE R A, et al. Upregulation of YKL-40 promotes metastatic phenotype and correlates with poor prognosis and therapy response in patients with colorectal cancer[J]. Cells, 2022, 11(22): 3568.
[20] CHEN A P, JIANG Y N, LI Z W, et al. Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma[J]. J Clin Invest, 2021, 131(16): e147552.
[21] SUZUKI H, BOKI H, KAMIJO H, et al. YKL-40 promotes proliferation of cutaneous T-cell lymphoma tumor cells through extracellular signal-regulated kinase pathways[J]. J Invest Dermatol, 2020, 140(4): 860-868.
[22] OCHMAN B, MIELCARSKA S, KULA A, et al. Do elevated YKL-40 levels drive the immunosuppressive tumor microenvironment in colorectal cancer- assessment of the association of the expression of YKL-40, MMP-8, IL17A, and PD-L1 with coexisting type 2 diabetes, obesity, and active smoking[J]. Curr Issues Mol Biol, 2023, 45(4): 2781-2797.
[23] DÜNDAR A, CAFER V, ASLANHAN H, et al. Increased visinin-like protein-1, YKL-40, lipocalin-2, and IL-23 levels in patients with migraine[J]. Neurol Res, 2023, 45(2): 97-102.

Relationships between serum Lipocalin-2 and YKL-40 levels on therapeutic effect of neoadjuvant radiotherapy and chemotherapy in esophageal cancer patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHAO Liran, BU Liang. Bioinformatics analysis of key gene expression in esophageal cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 374-381.
[2]	FU Jing, LIU Qing, YU Haiye, WANG Lei. Regulation of malignant phenotype of esophageal squamous carcinoma cells by miR-495 via suppressing the expression of RNF113A [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 202-208,214.
[3]	LU Dapeng, ZHAO Weilin, WANG Yuqiang, LU Hongchao, WEI Shuangping. Survival follow-up survey of esophageal cancers and establishment of a nomogram prognosis prediction model [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 37-42.
[4]	FENG Zhiyin, WU Yixian, HA Xiaodan, CHEN Wujin, LI Xiumei, DONG Juanjuan. Detection of p38MAPK gene in plasma cell-free DNA among patients with high incidence of esophageal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 105-109.
[5]	JIAO Wenjing, GUO Xiujuan, MA Ming, SHAO Junguo, ZHANG Jinyan. Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 124-128.
[6]	CHEN Wanxian, WANG Simeng, CHEN Zhangyu, WANG Panji, ZHENG Chunwen, LI Enmin, XU Liyan. CASIN, a CDC42 inhibitor, inhibited viability and migration of esophageal carcinoma cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 136-142.
[7]	FENG Min, ABBIE·Mohetar, SHI Jingyi, ZUKELAI·Alijiang, LI Yongxiang, YAN Changshun, LI Xiumei. Expression of miR-143, miR-145 and Survivin mRNA in esophageal cancers among Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 29-32.
[8]	MA Lili, ZHANG Shuli, LI Qin, XU Peng, FENG Min, LI Xiumei. Screening and identification of differentially expressed miRNAs in esophageal cancers among Xinjiang Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 52-56.
[9]	YANG Xingxiao, ZOU Naiyi, LI Qiaofang, ZHANG Xueyuan, SONG Heng, LIU Zhikun, MA Ming, SHAN Baoen, ZHU Shuchai. Significance in expression of RNF2 and PCNA proteins in esophageal squamous cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 254-257.
[10]	HE Shuzhi, ZHAO Yue, LIU Yang, YANG Liucai, CHEN Ping, LIU Ran. Evaluation of the quality of life among esophageal cancer patients who received chemotherapy [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 437-444,449.
[11]	LI Xiumei, GUO Qiong, WANG Dong, CHEN Yan, LI Hui, CHEN Hongming, LI Huiwu. Expression and significance of miR-143, MMP-2 and TIMP-1 in esophageal cancer in Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 32-35,40.
[12]	CAO Ying-ya，CHE Yi-qun，CHEN Qun，MA Wen-tao，LIU Yang，HAO Jia-jie，CAI Yan，LU Wei-hua，WANG Ming-rong，ZHANG Yu. Establishment of an esophageal cell line with stable expression of inducible PLK1-shRNA [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(5): 348-352.
[13]	LI Xiu-mei，LI Hui，JIANG Xiao-fang，CHEN Yan，CHEN Hong-ming，LI Hui-wu. Expression of Survivin shRNA interference on CDK4 in esophageal ECA109 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(4): 298-304.
[14]	TIAN Wei，ZHANG Hui-xia，CHEN Yan. Methylation of the CpG island in MT-3 gene in esophageal carcinoma in Kazaks and Hans in Xinjiang [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(5): 357-359.
[15]	CHEN Lan-ying，SONG Wei，YANG Hai-bo，YU Huai-bin，LIU Ya-jun，ZHI Shuang-cheng，YANG Feng. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(3): 201-204.